Stockscreener 앱 받기
14.06
5.00%
-0.74
시간 외 거래:
14.23
0.17
+1.21%
전일 마감가:
$14.80
열려 있는:
$14.71
하루 거래량:
395.73K
Relative Volume:
0.72
시가총액:
$770.23M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.89%
1개월 성능:
-19.33%
6개월 성능:
+34.29%
1년 성능:
+6.35%
1일 변동 폭
$13.80
$15.06
1주일 범위
$13.80
$16.00
52주 변동 폭
$7.80
$19.71
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
14.06 | 810.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-29 | 개시 | Citizens JMP | Mkt Perform |
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
FMR LLC's Strategic Acquisition of Bicara Therapeutics Inc Shares - GuruFocus
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-04 16:21:43 - baoquankhu1.vn
Aug Technicals: Why is Bicara Therapeutics Inc stock going downTrade Risk Assessment & Fast Entry Momentum Alerts - baoquankhu1.vn
Aug Breakouts: Why is Bicara Therapeutics Inc stock going downWeekly Investment Report & Consistent Growth Stock Picks - baoquankhu1.vn
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Citizens Initiates Coverage of Bicara Therapeutics (BCAX) with Market Outperform Recommendation - Nasdaq
Bicara Therapeutics (NASDAQ:BCAX) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating By Investing.com - Investing.com Nigeria
Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating - Investing.com Canada
Ivan Hyep Sells 1,882 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - Defense World
Hyep Ivan, CFO of Bicara Therapeutics, sells $34,162 in BCAX stock - Investing.com Canada
Ryan Cohlhepp Sells 3,828 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Stocks showing improving market leadership: Bicara Therapeutics earns 82 RS rating - MSN
Bicara Therapeutics (BCAX) Investor Outlook: A 74.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Upgrade: Should I set a stop loss on Bicara Therapeutics IncOptions Play & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Stocks To Watch: Bicara Therapeutics Sees Relative Strength Rating Rise To 81 - Investor's Business Daily
Quarterly Earnings: What are analysts price targets for Bicara Therapeutics IncVolume Spike & Real-Time Buy Signal Alerts - baoquankhu1.vn
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target - TipRanks
Bicara Therapeutics Inc. (BCAX) Investor Outlook: Exploring an 84% Potential Upside in Biotechnology - DirectorsTalk Interviews
Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), NewAmsterdam Pharma Company (NAMS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Does Bicara Therapeutics Inc align with a passive investing strategyDividend Hike & Weekly Market Pulse Updates - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock - Investing.com
How cyclical is Bicara Therapeutics Inc.’s revenue stream2025 Market Outlook & Daily Growth Stock Investment Tips - Bollywood Helpline
Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush - Defense World
Growth Report: Will Bicara Therapeutics Inc. stock continue upward momentumJuly 2025 Opening Moves & Weekly Breakout Watchlists - Bộ Nội Vụ
Wedbush Reaffirms Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Bicara selects optimal dose for head and neck cancer drug in pivotal study - Investing.com Nigeria
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7%Time to Sell? - MarketBeat
BCAX: Ficerafusp alfa shows deep, durable responses and blockbuster potential in head and neck cancer - TradingView
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook - Sahm
Bicara Sets Phase 3 Path for Ficerafusp Alfa - TipRanks
Bicara Therapeutics announces phase 3 optimal dose and provides 2026 corporate outlook - marketscreener.com
Bicara Therapeutics Inc Announces Phase 3 Optimal Dose and 2026 Outlook - TradingView
Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook - TradingView
Published on: 2026-01-12 06:24:33 - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Trading 7.8% Higher – Should You Buy? - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationWeekly Trade Review & Precise Trade Entry Recommendations - ulpravda.ru
BTIG Research Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc.Common Stock (NQ: BCAX - FinancialContent
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.8%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at BTIG Research - MarketBeat
Published on: 2026-01-09 02:43:58 - Улправда
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 Breakouts & Safe Entry Trade Signal Reports - Улправда
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
1.24%
0.19%
자본화:
|
볼륨(24시간):